hGHRH(1-40)OH vs Macimorelin
Head-to-head comparison of hGHRH(1-40)OH (Human growth hormone-releasing factor (1-40) hydroxyl) and Macimorelin (Macimorelin acetate (AEZS-130)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | hGHRH(1-40)OH | Macimorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Full Name | Human growth hormone-releasing factor (1-40) hydroxyl | Macimorelin acetate (AEZS-130) |
| Molecular Weight | N/A | N/A |
| Half-Life | 5-20 minutes | about 4-6 hours |
| Amino Acids | 40 | N/A |
| Typical Dose | 1-2 mcg/kg | 0.5 mg/kg single oral dose |
| Route | Subcutaneous/IV | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 85 | 120 |
| Research Status | Clinical Research | Clinical |
hGHRH(1-40)OH Benefits
- ✓GH secretion research
- ✓fragment-activity comparison
- ✓receptor binding studies
- ✓axis physiology modeling
Macimorelin Benefits
- ✓diagnostic GH stimulation
- ✓single oral dose
- ✓rapid measurable GH response
- ✓high clinical utility
hGHRH(1-40)OH Dosing
1-2 mcg/kg SC or IV in acute research settings|single-bolus GH stimulation protocols|repeated low-dose administration in comparative studies
Macimorelin Dosing
0.5 mg/kg orally as a single dose|fasted testing conditions|serial GH sampling after administration
hGHRH(1-40)OH Side Effects
- ⚠flushing
- ⚠headache
- ⚠lightheadedness
Macimorelin Side Effects
- ⚠dysgeusia or taste disturbance
- ⚠nausea
- ⚠headache
Research Overview
hGHRH(1-40)OH
Human GHRF(1-40)OH has been studied to understand how truncation of the native hormone changes biological potency and half-life. It is a common research tool for mapping minimal active sequences within the GHRH family.
Macimorelin
Macimorelin has been validated in clinical testing as an oral alternative to injectable GH stimulation tests. Its short-term use makes it a useful translational tool for evaluating pituitary GH reserve.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.